Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Pain ; 14: 1744806918767560, 2018.
Article in English | MEDLINE | ID: mdl-29607715

ABSTRACT

Treating bone cancer pain continues to be a clinical challenge and underlying mechanisms of bone cancer pain remain elusive. Here, we reported that sonic hedgehog signaling plays a critical role in the development of bone cancer pain. Tibia bone cavity tumor cell implantation produces bone cancer-related mechanical allodynia, thermal hyperalgesia, and spontaneous and movement-evoked pain behaviors. Production and persistence of these pain behaviors are well correlated with tumor cell implantation-induced up-regulation and activation of sonic hedgehog signaling in primary sensory neurons and spinal cord. Spinal administration of sonic hedgehog signaling inhibitor cyclopamine prevents and reverses the induction and persistence of bone cancer pain without affecting normal pain sensitivity. Inhibiting sonic hedgehog signaling activation with cyclopamine, in vivo or in vitro, greatly suppresses tumor cell implantation-induced increase of intracellular Ca2+ and hyperexcitability of the sensory neurons and also the activation of GluN2B receptor and the subsequent Ca2+-dependent signals CaMKII and CREB in dorsal root ganglion and the spinal cord. These findings show a critical mechanism underlying the pathogenesis of bone cancer pain and suggest that targeting sonic hedgehog signaling may be an effective approach for treating bone cancer pain.


Subject(s)
Bone Neoplasms/complications , Cancer Pain/etiology , Cancer Pain/pathology , Hedgehog Proteins/metabolism , Sensory Receptor Cells/metabolism , Sensory Receptor Cells/pathology , Signal Transduction , Animals , Calcium/metabolism , Cancer Pain/metabolism , Cell Line, Tumor , Female , Ganglia, Spinal/metabolism , Ganglia, Spinal/pathology , Intracellular Space/metabolism , Neoplasm Transplantation , Nociception , Rats, Sprague-Dawley , Spinal Cord/pathology , Up-Regulation
2.
J Pain ; 19(2): 186-195, 2018 02.
Article in English | MEDLINE | ID: mdl-29079540

ABSTRACT

Glial cell hyperactivity has been proposed to be responsible for chronic pain, however, the mechanisms remain unclear. Interleukin (IL)-18, released from glial cells, has been reported to be involved in neuropathic pain. In this study, we investigated the role of IL-18 in bone cancer pain. Bone cancer pain was mimicked by injecting Walker-256 mammary gland carcinoma cells into the intramedullary space of the tibia in rats. Expression and location of IL-18 and the IL-18 receptor were tested. To investigate the contribution of IL-18 signaling to bone cancer pain, IL-18 binding protein and recombinant IL-18 were used. To investigate the mechanisms of glial cells effects, MK801, N-methyl-D-aspartate (NMDA) receptor inhibitor, and Src kinase-specific inhibitor PP1 were used. Tumor cell implantation (TCI) treatment increased expression of IL-18 and IL-18 receptor in spinal cord. The time course of IL-18 upregulation was correlated with TCI-induced pain behaviors. Blocking the IL-18 signaling pathway prevented and reversed bone cancer-related pain behaviors. Meanwhile, blocking IL-18 signaling also suppressed TCI-induced glial cell hyperactivity, as well as activation of GluN2B and subsequent Ca2+-dependent signaling. Spinal administration of recombinant IL-18 in naive rat induced significant mechanical allodynia, as well as GluN2B activation. However, intrathecal injection of MK801 failed to suppress recombinant IL-18-induced GluN2B phosphorylation, whereas Src kinase inhibitor PP1 significantly inhibited IL-18-induced GluN2B activation. IL-18-mediated glial-glia and glial-neuron interaction may facilitate bone cancer pain. Blocking IL-18 signaling may effectively prevent and/or suppress bone cancer pain. PERSPECTIVE: IL-18 signaling may be a new target for cancer pain therapy.


Subject(s)
Cancer Pain/pathology , Interleukin-18/metabolism , Neuroglia/physiology , Neurons/physiology , Spinal Cord/pathology , Animals , Bone Neoplasms/complications , Cancer Pain/drug therapy , Cancer Pain/etiology , Carcinoma/complications , Disease Models, Animal , Hyperalgesia/chemically induced , Injections, Spinal , Interleukin-18/adverse effects , Rats , Receptors, Interleukin-18/metabolism , Receptors, N-Methyl-D-Aspartate/metabolism , Signal Transduction/drug effects , Spinal Cord/drug effects , Spinal Cord/metabolism , Xenograft Model Antitumor Assays
3.
Mediators Inflamm ; 2015: 752512, 2015.
Article in English | MEDLINE | ID: mdl-26819501

ABSTRACT

OBJECTIVE: The present study is to investigate the analgesic roles of L-THP in rats with bone cancer pain caused by tumor cell implantation (TCI). METHODS: Thermal hyperalgesia and mechanical allodynia were measured at different time points before and after operation. L-THP (20, 40, and 60 mg/kg) were administrated intragastrically at early phase of postoperation (before pain appearance) and later phase of postoperation (after pain appearance), respectively. The concentrations of TNF-α, IL-1ß, and IL-18 in spinal cord were measured by enzyme-linked immunosorbent assay. Western blot was used to test the activation of astrocytes and microglial cells in spinal cord after TCI treatment. RESULTS: TCI treatment induced significant thermal hyperalgesia and mechanical allodynia. Administration of L-THP at high doses significantly prevented and/or reversed bone cancer-related pain behaviors. Besides, TCI-induced activation of microglial cells and the increased levels of TNF-α and IL-18 were inhibited by L-THP administration. However, L-THP failed to affect TCI-induced astrocytes activation and IL-1ß increase. CONCLUSION: This study suggests the possible clinical utility of L-THP in the treatment of bone cancer pain. The analgesic effects of L-THP on bone cancer pain maybe underlying the inhibition of microglial cells activation and proinflammatory cytokines increase.


Subject(s)
Berberine Alkaloids/pharmacology , Bone Neoplasms/physiopathology , Microglia/drug effects , Pain, Intractable/drug therapy , Animals , Dose-Response Relationship, Drug , Female , Hyperalgesia/drug therapy , Interleukin-18/analysis , Microglia/physiology , Neoplasm Transplantation , Rats , Rats, Sprague-Dawley , Tumor Necrosis Factor-alpha/analysis
4.
Spine (Phila Pa 1976) ; 39(19): 1533-41, 2014 Sep 01.
Article in English | MEDLINE | ID: mdl-24921837

ABSTRACT

STUDY DESIGN: A prospective, randomized experimental research. OBJECTIVE: To demonstrate the role of cGMP (cyclic guanosine monophosphate)-cGKI (cGMP-dependent protein kinase I) pathway in dorsal root ganglia (DRG) in bone cancer pain. SUMMARY OF BACKGROUND DATA: Treating bone cancer pain continues to possess a major clinical challenge because the specific cellular and molecular mechanisms underlying bone cancer pain remain elusive. cGMP and cGMP-dependent protein kinases pathway in DRG plays important role in nerve injury-induced hyperexcitability of DRG neurons, as well as neuropathic pain, however, whether this pathway participates in bone cancer pain is unknown. METHODS: The rat model of bone cancer pain was produced by intramedullary injection of rat breast cancer cells (Walker 256) into right tibia. Thermal hyperalgesia and mechanical allodynia were measured before and after administration of inhibitor of cGMP-cGKs pathway (Rp-8-pCPT-cGMPS). Immunofluorescence and reverse transcription-polymerase chain reaction were used to reflect expression of cGKI in DRG neurons, whereas the concentration of cGMP in DRG was tested using enzyme-linked immunosorbent assay method. Whole-cell patch clamp was used to record the hyperexcitability of small neurons in DRG with or without cGKs inhibitor after tumor cell implantation (TCI). RESULTS: TCI treatment significantly increased the concentration of cGMP in DRG and activity of cGKs in DRG and the spinal cord. TCI treatment also induced upregulation of cGKI messenger ribonucleic acid and protein in DRG, as well as enhanced hyperexcitability in DRG neurons. Spinal administration of Rp-8-pCPT-cGMPS, cGMP-cGKs inhibitor, significantly suppressed TCI-induced activation of cGMP-cGKI signaling, and hyperexcitability of DRG neurons. Meanwhile, in vivo intrathecal delivery of the Rp-8-pCPT-cGMPS significantly prevented and suppressed TCI-induced hyperalgesia and allodynia. CONCLUSION: From these results, we confirm that TCI treatment activates cGMP-cGKI signaling pathway and continuing activation of this pathway in DRG is required for hyperalgesia and/or hyperalgesia and allodynia after TCI treatment. LEVEL OF EVIDENCE: N/A.


Subject(s)
Bone Neoplasms/secondary , Carcinoma 256, Walker/secondary , Cyclic GMP-Dependent Protein Kinase Type I/physiology , Cyclic GMP/physiology , Ganglia, Spinal/physiopathology , Hyperalgesia/physiopathology , Neoplasm Proteins/physiology , Sensory Receptor Cells/physiology , Tibia , Animals , Bone Neoplasms/physiopathology , Carcinoma 256, Walker/physiopathology , Cyclic GMP/analogs & derivatives , Cyclic GMP/pharmacology , Cyclic GMP-Dependent Protein Kinase Type I/antagonists & inhibitors , Cyclic GMP-Dependent Protein Kinase Type I/biosynthesis , Cyclic GMP-Dependent Protein Kinase Type I/genetics , Enzyme Induction , Female , Hot Temperature , Hyperalgesia/etiology , Neoplasm Proteins/antagonists & inhibitors , Neoplasm Proteins/biosynthesis , Neoplasm Proteins/genetics , Pain Threshold , Patch-Clamp Techniques , Protein Kinase Inhibitors/pharmacology , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , RNA, Neoplasm/biosynthesis , RNA, Neoplasm/genetics , Random Allocation , Rats , Rats, Sprague-Dawley , Thionucleotides/pharmacology , Tibia/innervation , Touch
5.
CNS Neurosci Ther ; 17(6): 605-11, 2011 Dec.
Article in English | MEDLINE | ID: mdl-20875045

ABSTRACT

INTRODUCTION: Sevoflurane is well known to exert a neuroprotective effect through anesthetic preconditioning. However, its effects on postconditioning, a neuroprotective phenomenon following an insult, have not been well studied. AIMS: In this study, we examined the ability of sevoflurane to induce postconditioning in rat hippocampal slices, in vitro. RESULTS: 2%, 4%, and 6% sevoflurane reduced neurophysiologic and morphologic neuronal injury following oxygen-glucose deprivation (OGD) and reperfusion. The quantity of damaged neurons was significantly reduced on immunofluorescence staining; excitatory amino acids (Asp, Glu) increased and inhibitory amino acids (GABA) decreased significantly. The effect was concentration-dependent. CONCLUSION: Postconditioning with sevoflurane reduces neuronal damage after OGD-reperfusion injury in the CA1 area of rat hippocampus, in vitro.


Subject(s)
Anesthetics, Inhalation/pharmacology , Glucose/deficiency , Hippocampus/pathology , Hypoxia, Brain/drug therapy , Methyl Ethers/pharmacology , Neuroprotective Agents , Reperfusion Injury/drug therapy , Amino Acids/cerebrospinal fluid , Amino Acids/metabolism , Animals , Coloring Agents , Electrophysiological Phenomena , Evoked Potentials/physiology , Fluorescent Antibody Technique , Hippocampus/drug effects , Hypoxia, Brain/pathology , Male , Microscopy, Electron , Microscopy, Fluorescence , Neurons/pathology , Neurotransmitter Agents/cerebrospinal fluid , Neurotransmitter Agents/metabolism , Propidium , Rats , Rats, Sprague-Dawley , Reperfusion Injury/pathology , Sevoflurane
6.
Eur J Pharmacol ; 614(1-3): 44-9, 2009 Jul 01.
Article in English | MEDLINE | ID: mdl-19445923

ABSTRACT

The present study was designed to investigate the role of glycine receptors in analgesia induced by injection of glycine in vivo. Glycine was injected intracerebroventricularly or intrathecally and strychnine, a glycine receptor antagonist, was injected intracerebroventricularly or intrathecally before glycine injection. The effects on the pain threshold index in hot-plate test and the writhing times in acetic acid-induced writhing test were observed. The locomotor activity and motor performance (rotarod test) were also observed. The dosages of glycine and strychnine we choose had no effect on locomotor activity or motor performance in conscious mice. Glycine increased the pain threshold index in hot-plate test and decreased the writhing times of the mice. Strychnine antagonized the effects induced by glycine above. These results demonstrated that intracerebroventricular or intrathecal injection of glycine can produce analgesia in thermal nociception and chemical nociception in vivo, which is mediated by glycine receptors.


Subject(s)
Analgesics/administration & dosage , Analgesics/pharmacology , Glycine/administration & dosage , Glycine/pharmacology , Hot Temperature/adverse effects , Pain/drug therapy , Receptors, Glycine/metabolism , Acetic Acid/adverse effects , Analgesia , Animals , Behavior, Animal/drug effects , Female , Injections, Intraventricular , Injections, Spinal , Male , Mice , Motor Activity/drug effects , Pain/chemically induced , Pain/metabolism , Pain/physiopathology , Pain Threshold/drug effects , Receptors, Glycine/antagonists & inhibitors , Rotarod Performance Test , Strychnine/administration & dosage , Strychnine/pharmacology
7.
Eur J Pharmacol ; 584(1): 159-65, 2008 Apr 14.
Article in English | MEDLINE | ID: mdl-18328478

ABSTRACT

The pathogenesis of acute lung injury/acute respiratory distress syndrome (ARDS) is complex and involves multiple signal transduction processes. It is believed that p38MAPK (mitogen-activated protein kinase) is one of the most kinases in inflammatory signaling. At present study, we demonstrated the role of p38MAPK in lipopolysaccharide (LPS)-induced acute lung injury with pharmacologic p38MAPK inhibition by SB203580. SB203580, p38MAPK specific inhibitor, was injected (10 mg/kg, i.v.) 30 min before LPS administration (5 mg/kg, i.v.). The hematoxylin-eosin staining of lung tissues showed that p38MAPK inhibition significantly attenuated the pulmonary inflammatory responses induced by LPS. Moreover, SB203580 can also inhibit the inflammatory cytokine release, and reduce the mortality rate of LPS-induced acute lung injury. Further, western blot analysis that showed SB203580 administration can inhibit the activation of NF-kappaB, which was associated with the inhibition of IkappaBalpha degradation in cytoplasm. These data suggest that p38MAPK signaling may be involved in the activation of NF-kappaB, and activation of p38MAPK signaling may be one of the mechanisms of acute lung injury.


Subject(s)
Imidazoles/pharmacology , Lung/drug effects , NF-kappa B/metabolism , Protein Kinase Inhibitors/pharmacology , Pyridines/pharmacology , Respiratory Distress Syndrome/drug therapy , Signal Transduction/drug effects , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors , Animals , Bronchoalveolar Lavage Fluid/chemistry , Cytokines/metabolism , Disease Models, Animal , Enzyme Activation , I-kappa B Proteins/metabolism , Imidazoles/administration & dosage , Inflammation Mediators/metabolism , Injections, Intravenous , Interleukin-6/metabolism , Lipopolysaccharides , Lung/enzymology , Lung/metabolism , Lung/pathology , Male , NF-KappaB Inhibitor alpha , Organ Size , Protein Kinase Inhibitors/administration & dosage , Pyridines/administration & dosage , Rats , Rats, Sprague-Dawley , Respiratory Distress Syndrome/chemically induced , Respiratory Distress Syndrome/metabolism , Respiratory Distress Syndrome/pathology , Time Factors , Tumor Necrosis Factor-alpha/metabolism , p38 Mitogen-Activated Protein Kinases/metabolism
8.
Pharmacology ; 81(1): 32-40, 2008.
Article in English | MEDLINE | ID: mdl-17785997

ABSTRACT

BACKGROUND AND OBJECTIVES: Lidocaine has been reported to attenuate the inflammatory response in addition to its anesthetic activity, but the mechanisms are poorly understood. The objective of this study is to determine if lidocaine prior to endotoxemia diminishes pulmonary dysfunction by blocking the NF-kappaB activation. METHODS: Rats were assigned to: (1) control (0.9% sodium chloride); (2) lipopolysaccharides (LPS); (3) LPS + lidocaine 1 mg/kg; (4) LPS + lidocaine 2 mg/kg, and (5) LPS + lidocaine 4 mg/kg. The LPS and LPS + lidocaine 4 mg/kg groups were subjected to 1-, 3-, 6- and 12-hour time points. To investigate the activation of NF-kappaB, the expression of NF-kappaB in the nuclear and I kappaB alpha in the cytosol extracts were analyzed by Western blot. The concentration of TNF-alpha and IL-6 in serum was detected by ELISA. The pathologic changes of the lung were observed using HE staining. RESULTS: After i.p. injection of LPS, the expression of NF-kappaB in the nuclear extracts was significantly increased and I kappaB alpha in the cytosol extracts was markedly decreased. The concentration of TNF-alpha and IL-6 in serum was increased. Pathological examination showed that the normal structure of the lung was destroyed badly. However, lidocaine reversed the above results. CONCLUSION: Lidocaine attenuates LPS-induced lung injury via mechanisms involving inhibiting NF-kappaB activation and cytokine release, which implies that lidocaine may be a potential anti-inflammatory agent in endotoxemia.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Lidocaine/therapeutic use , NF-kappa B/antagonists & inhibitors , Respiratory Distress Syndrome/prevention & control , Animals , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/pharmacology , Blotting, Western , Cytokines/blood , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Lidocaine/administration & dosage , Lidocaine/pharmacology , Lipopolysaccharides , Lung/drug effects , Lung/immunology , Lung/pathology , Male , NF-kappa B/biosynthesis , Rats , Rats, Sprague-Dawley , Respiratory Distress Syndrome/chemically induced , Respiratory Distress Syndrome/immunology , Respiratory Distress Syndrome/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...